Pfizer and Moderna’s COVID-19 vaccines offer lasting protection
April 12, 2023
Source: drugdu
139
Study finds on April 7th, 2023, Pharmaceutical Technology reported that a new study has found that Pfizer and Moderna's COVID-19 vaccines offer lasting protection against the virus. The study, which was published in the New England Journal of Medicine, found that people who received either vaccine had robust and persistent antibody and T cell responses against SARS-CoV-2, the virus that causes COVID-19, even six months after receiving the second dose.
The study followed 2,500 healthcare workers who received either the Pfizer or Moderna vaccine and found that their immune responses remained strong over time. The researchers noted that while antibody levels did decline over time, the levels were still high enough to provide protection against the virus.
The findings are significant because they suggest that the vaccines are likely to provide long-term protection against COVID-19. The study also provides reassurance that the vaccines are effective against new variants of the virus.
Reference:
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections May 16, 2024
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results May 16, 2024
- Results from FRONTIER 2 Trial Show Promise of Mim8 as a Potential Treatment for Hemophilia A May 16, 2024
- AbbVie, Gilgamesh Pharmaceuticals Agree to Terms on a Collaboration to Develop Advanced Therapies for Psychiatric Disorders May 16, 2024
- BBSRC invests £48m in Babraham Institute to advance lifelong health research May 16, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
